STOCK TITAN
  1. Home
  2. Sec-filings
  3. NEUP
  4. [Form 4] Neuphoria Therapeutics Inc. Insider Trading Activity

NEUP Form 4: 639,110 shares purchased; 875,328 held indirectly

Filing Impact
(Very High)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Neuphoria Therapeutics Inc. (NEUP) disclosed an insider purchase on a Form 4. Reporting persons tied to Lynx1 Master Fund LP bought 639,110 shares of common stock on 10/21/2025 at a weighted average price of $5.137. The filing notes the trades occurred across prices from $4.96 to $5.20. After the transaction, the filing reports 875,328 shares beneficially owned on an indirect basis. The reporting person’s relationship box indicates Director.

The filing explains that the securities are held by Lynx1 Master Fund LP, with Lynx1 Capital Management LP as investment manager and Weston Nichols as the sole member of the manager’s general partner, and includes customary beneficial ownership disclaimers.

Positive

  • None.

Negative

  • None.
Insider Lynx1 Capital Management LP, Nichols Weston
Role 10% Owner | 10% Owner
Bought 639,110 shs ($3.28M)
Type Security Shares Price Value
Purchase Common stock, $0.00001 par value per share 639,110 $5.137 $3.28M
Holdings After Transaction: Common stock, $0.00001 par value per share — 875,328 shares (Indirect, See footnote)
Footnotes (1)
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.96 to $5.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lynx1 Capital Management LP
(Last) (First) (Middle)
D81 CALLE C, STE 301, PMB 1202
(Street)
DORADO PR 00646-2051
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Neuphoria Therapeutics Inc. [ NEUP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock, $0.00001 par value per share 10/21/2025 P 639,110 A $5.137(1) 875,328 I See footnote(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Lynx1 Capital Management LP
(Last) (First) (Middle)
D81 CALLE C, STE 301, PMB 1202
(Street)
DORADO PR 00646-2051
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Nichols Weston
(Last) (First) (Middle)
D81 CALLE C, STE 301, PMB 1202
(Street)
DORADO PR 00646-2051
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.96 to $5.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
2. The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.
Lynx1 Capital Management LP, By: Lynx1 Capital Management GP LLC, its general partner, By: /s/ Weston Nichols, Sole Member 10/23/2025
/s/ Weston Nichols 10/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Neuphoria Therapeutics (NEUP) report on this Form 4?

An insider-related group purchased 639,110 shares of common stock on 10/21/2025.

What was the price paid for the NEUP shares?

The filing reports a weighted average price of $5.137, with trades from $4.96 to $5.20.

How many NEUP shares are beneficially owned after the transaction?

The filing shows 875,328 shares beneficially owned on an indirect basis following the purchase.

Who holds the NEUP shares reported in the filing?

The securities are held by Lynx1 Master Fund LP, with Lynx1 Capital Management LP as investment manager.

Who is associated with the investment manager in the NEUP filing?

Weston Nichols is the sole member of the general partner of the investment manager, per the filing.

What relationship to Neuphoria is indicated in the Form 4?

The relationship box indicates Director for the reporting person.